Long-term Extension Study of the Safety, Tolerability, and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-36)

Inclusion Criteria: * Completion of a lead-in study (NCT00891462) Exclusion Criteria: * Use or anticipated use of any medication prohibited in this study * Evidence of abnormal clinical laboratory values, vital signs, or electrocardiographic (ECG) results or the presence of abnormities in physical examination findings * The presence of anti-cholinergic effects (eg, dry mouth, urinary retention, narrow angle glaucoma) * QTcB of \>500 msec on both the pre-dose and post-dose ECG * Women who are pregnant, intend to become pregnant, or are breast-feeding * A life expectancy of less than 1 year * Noncompliance with IP dosing and/or attending clinic visits during the lead-in study * Significant interruption of double-blind therapy during the transition from the lead-in study into the extension study.